[Antiplatelet therapy after aspirin-induced upper gastrointestinal bleeding]

Area of Science:

• Gastroenterology
• Cardiology
• Pharmacology

Background:

• Aspirin is commonly replaced by clopidogrel in patients with aspirin-induced gastrointestinal (GI) intolerance.
• Recent evidence suggests a combination of aspirin and a proton pump inhibitor (PPI) may be a superior alternative.

Purpose of the Study:

• To evaluate the efficacy and safety of aspirin plus a PPI compared to clopidogrel for preventing recurrent GI bleeding.
• To assess the cost-effectiveness of aspirin plus a PPI versus clopidogrel.

Main Methods:

• Comparative analysis of clinical trial data (e.g., CAPRIE, CURE studies).
• Review of studies investigating aspirin and esomeprazole combination therapy for GI bleeding prevention.

Main Results:

• No clinically significant difference in efficacy between aspirin and clopidogrel was observed in major trials.
• Similar bleeding incidence rates were noted for aspirin doses below 160 mg.
• Aspirin plus esomeprazole demonstrated superiority over clopidogrel in preventing recurrent GI bleeding.
• Aspirin plus a PPI represents the most cost-effective treatment option.

Conclusions:

• Combining aspirin with a PPI is a highly effective and economical strategy for patients with GI intolerance to aspirin.
• This combination therapy offers a favorable alternative to clopidogrel for preventing recurrent GI bleeding.